CryoPort (CYRX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• CryoPort (CYRX) is expected to release its Q2 2025 earnings report on August 5th, with analysts predicting an earnings loss of ($0.20) per share and revenues of $41.74 million.
• The company recently saw its stock price affected, opening at $7.65 and down 2.5% as it approaches earnings release, with a market cap of $383.57 million.
• Analysts have mixed opinions on CryoPort’s stock, with price targets ranging from $7.00 to $15.00 and an overall rating of "Moderate Buy" based on recent evaluations.

CryoPort (NASDAQ:CYRX - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect CryoPort to post earnings of ($0.20) per share and revenue of $41.74 million for the quarter. CryoPort has set its FY 2025 guidance at EPS.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The firm had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. On average, analysts expect CryoPort to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CryoPort Stock Performance

CYRX traded down $0.02 on Wednesday, hitting $7.54. 361,022 shares of the company's stock were exchanged, compared to its average volume of 403,363. The firm has a market cap of $378.06 million, a PE ratio of -3.22 and a beta of 1.89. CryoPort has a twelve month low of $4.58 and a twelve month high of $9.66. The stock has a fifty day moving average of $6.98 and a two-hundred day moving average of $6.60. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51.

Insider Activity

In other CryoPort news, Director Robert J. Hariri sold 12,500 shares of the firm's stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $6.10, for a total value of $76,250.00. Following the sale, the director directly owned 8,061 shares in the company, valued at $49,172.10. This trade represents a 60.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jerrell Shelton sold 151,304 shares of CryoPort stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $6.81, for a total transaction of $1,030,380.24. Following the sale, the chief executive officer owned 912,419 shares in the company, valued at approximately $6,213,573.39. This trade represents a 14.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 490,447 shares of company stock valued at $3,337,198. 10.00% of the stock is owned by corporate insiders.

Institutional Trading of CryoPort

A hedge fund recently raised its stake in CryoPort stock. AQR Capital Management LLC boosted its position in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 285.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 262,596 shares of the company's stock after purchasing an additional 194,482 shares during the period. AQR Capital Management LLC owned about 0.52% of CryoPort worth $1,597,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 92.90% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Stephens assumed coverage on shares of CryoPort in a research report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 target price for the company. Guggenheim reissued a "buy" rating and set a $10.00 target price on shares of CryoPort in a research note on Wednesday, April 16th. BTIG Research reduced their price target on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, July 7th. Roth Mkm reissued a "buy" rating and set a $15.00 target price on shares of CryoPort in a research note on Tuesday, April 1st. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of CryoPort in a research report on Thursday, May 8th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $11.11.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.